An independent central radiology review team assessed SEGA response ( at least a 50 % reduction from baseline in total volume of all target SEGAs ; the primary endpoint ) by MRI at 12 , 24 , and 48 weeks , then every year thereafter in all patients who received at least one dose of everolimus .